The study was conducted on a cohort of 133 patients with FD, and the main findings were as follows: (1) hs‐cTn was superior to NT‐proBNP for distinguishing patients with FC from those without; (2) the optimal hs‐cTn threshold is < 8.5 ng/L, ruling out FC with sensitivity 97.8% and NPV 97.2%; and (3) at this threshold, there is no difference in performance between hs‐cTnI and hs‐cTnT. The gene discussed is TNNI3; the disease is Fabry disease.